These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

153 related articles for article (PubMed ID: 7973217)

  • 1. The what, why and how of Bayesian clinical trials monitoring.
    Freedman LS; Spiegelhalter DJ; Parmar MK
    Stat Med; 1994 Jul 15-30; 13(13-14):1371-83; discussion 1385-9. PubMed ID: 7973217
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Application of Bayesian statistics to decision making during a clinical trial.
    Freedman LS; Spiegelhalter DJ
    Stat Med; 1992 Jan; 11(1):23-35. PubMed ID: 1557573
    [TBL] [Abstract][Full Text] [Related]  

  • 3. On some applications of Bayesian methods in cancer clinical trials.
    Greenhouse JB
    Stat Med; 1992 Jan; 11(1):37-53. PubMed ID: 1557574
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Is levamisole combined with fluorouracil efficient in colorectal cancer?].
    Theve T
    Lakartidningen; 1990 Sep; 87(37):2855-6. PubMed ID: 2214999
    [No Abstract]   [Full Text] [Related]  

  • 5. Timing the collaborative analysis of three trials comparing 5-FU plus folinic acid (FUFA) to surgery alone in the management of resected colorectal cancer: a National Cancer Institute of Canada Clinical Trials Group (NCIC-CTG) perspective.
    Pater JL
    Stat Med; 1994 Jul 15-30; 13(13-14):1337-40. PubMed ID: 7973214
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A Bayesian analysis of bivariate survival data from a multicentre cancer clinical trial.
    Gustafson P
    Stat Med; 1995 Dec; 14(23):2523-35. PubMed ID: 8746886
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Anything in modulation?
    Gray R; Hills R; Stowe R
    Ann Oncol; 2003 Sep; 14(9):1338-9. PubMed ID: 12954571
    [No Abstract]   [Full Text] [Related]  

  • 8. Bayesian subset analysis in a colorectal cancer clinical trial.
    Dixon DO; Simon R
    Stat Med; 1992 Jan; 11(1):13-22. PubMed ID: 1557569
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Tutorial in biostatistics Bayesian data monitoring in clinical trials.
    Fayers PM; Ashby D; Parmar MK
    Stat Med; 1997 Jun; 16(12):1413-30. PubMed ID: 9232762
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A biological perspective on the selection of stage II colorectal cancer patients for adjuvant chemotherapy.
    Iacopetta B
    Ann Oncol; 2002 Sep; 13(9):1510. PubMed ID: 12196384
    [No Abstract]   [Full Text] [Related]  

  • 11. Adjuvant chemotherapy for colorectal cancer.
    Maughan TS
    Br J Cancer; 2001 Nov; 85(10):1422-4. PubMed ID: 11720422
    [No Abstract]   [Full Text] [Related]  

  • 12. [Comparison of fluorouracil + folinic acid, fluorouracil + levamisole and fluorouracil + folinic acid + levamisole in Dukes' B and C colon cancer: NSABP Trial C-04].
    Schumacher K
    Strahlenther Onkol; 2000 May; 176(5):239-40. PubMed ID: 10847122
    [No Abstract]   [Full Text] [Related]  

  • 13. [Oxaliplatin in colorectal carcinoma: from palliation to cure].
    Arnheim K
    Onkologie; 2004 Aug; 27 Suppl 1():2-11. PubMed ID: 23570154
    [No Abstract]   [Full Text] [Related]  

  • 14. Fluorouracil plus levamisole as effective adjuvant therapy after resection of stage III colon carcinoma: a final report.
    Moertel CG; Fleming TR; Macdonald JS; Haller DG; Laurie JA; Tangen CM; Ungerleider JS; Emerson WA; Tormey DC; Glick JH; Veeder MH; Mailliard JA
    Ann Intern Med; 1995 Mar; 122(5):321-6. PubMed ID: 7847642
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Adaptive design: estimation and inference with censored data in a semiparametric model.
    Shen Y; Cheng Y
    Biostatistics; 2007 Apr; 8(2):306-22. PubMed ID: 16787996
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Robust Bayesian methods for monitoring clinical trials.
    Greenhouse JB; Wasserman L
    Stat Med; 1995 Jun; 14(12):1379-91. PubMed ID: 7569495
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Importance of 5-fluorouracil dose-intensity in a double randomised trial on adjuvant portal and systemic chemotherapy for Dukes B2 and C colorectal cancer.
    Focan C; Bury J; Beauduin M; Herman ML; Vindevoghel A; Lecomte M; Brohée D; Canon JL; Focan-Henrard D;
    Anticancer Res; 2000; 20(6C):4665-72. PubMed ID: 11205198
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cediranib plus FOLFOX/CAPOX versus placebo plus FOLFOX/CAPOX in patients with previously untreated metastatic colorectal cancer: a randomized, double-blind, phase III study (HORIZON II).
    Hoff PM; Hochhaus A; Pestalozzi BC; Tebbutt NC; Li J; Kim TW; Koynov KD; Kurteva G; Pintér T; Cheng Y; van Eyll B; Pike L; Fielding A; Robertson JD; Saunders MP
    J Clin Oncol; 2012 Oct; 30(29):3596-603. PubMed ID: 22965965
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prospective randomized trial of 5-fluorouracil versus 5-fluorouracil plus levamisole in the treatment of metastatic colorectal cancer: a Hoosier Oncology Group trial.
    Bandealy MT; Gonin R; Loehrer PJ; Monaco F; Einhorn LH
    Clin Cancer Res; 1998 Apr; 4(4):935-9. PubMed ID: 9563887
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Should FOLFOXIRI plus bevacizumab Be the standard first-line therapy in metastatic colorectal cancer?
    Nipp RD; Ryan DP
    Oncologist; 2015 Mar; 20(3):236-8. PubMed ID: 25660156
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.